Alnylam Pharmaceuticals, Inc.
Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases with unmet need. Alnylam’s first U.S. FDA-approved RNAi therapeutic is ONPATTRO® (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In addition, Alnylam has six investigational medicines in late-stage development. www.alnylam.com.